The clinical effectiveness of insulin glargine in patients with Type i diabetes in Brazil: Findings and implications

Future Virology

Volumn 12, Issue 9, 2017, Pages 519-527

  Marra, Lays P ^a   Araújo, Vânia E ^a   Oliveira, Gerusa C C ^a   Diniz, Leonardo M ^a   Guerra, Augusto A ^a   De Assis Acurcio, Francisco ^a   Godman, Brian ^b,c,d   Álvares, Juliana ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

Author keywords

Brazil; Comparative effectiveness research; Insulin glargine; Longitudinal studies; NPH insulin; Type I diabetes

Indexed keywords

CARBOHYDRATE; HEMOGLOBIN A1C; INSULIN GLARGINE; ISOPHANE INSULIN; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; BRAZIL; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; BLOOD; COST BENEFIT ANALYSIS; GLUCOSE BLOOD LEVEL; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT; AGE DISTRIBUTION; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; BLOOD GLUCOSE; BRAZIL; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 1; FEMALE; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN GLARGINE; INSULIN, ISOPHANE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85032725038     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/cer-2016-0099     Document Type: Article

References (31)

1. WHO: Global report on diabetes. http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257 eng.pdf?ua=1
2. Branchtein L, Matos MCG. Antidiabéticos. In:Farmacologia clínica: fundamentos da terapêutica racional (3rd Edition)) . Fuchs FD, Wannmacher L, Ferreira MBC (Eds.). Guanabara Koogan, Rio de Janeiro, Brazil, 832-844 (2006).
3. Caires de Souza AL, de Assis Acurcio F, Guerra Júnior AA, Rezende Macedo do Nascimento RC, Godman B, Diniz LM. Insulin glargine in a Brazilian state: should the government disinvest? An assessment based on a systematic review. Appl. Heal. Econ. Heal. Pol. 12(1), 19-32 (2014).
4. Marra LP, Araújo VE, Silva TBC et al. Clinical effectiveness and safety of analog glargine in Type I diabetes: a systematic review and meta-analysis. Diabetes Ther. 7(2), 241-258 (2016).
5. Olivera GC, Melo LM, Guerra Júnior AA, Alvares J. Efetividade clínica comparativa do análogo de insulina glargina para tratamento de pacientes acometidos por diabetes mellitus Tipo I. Value Health 18(7), A862-A863 (2015).
6. German Institute for Quality and Efficency in Healthcare (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus Type I: executive summary commission no. A05-01 (2010). www.iqwig.de/en/projects results/projects/drug assessment/a05 01 long acting insulin analogues in the treatment of diabetes mellitus type 1.1197.html
7. WHO, Review Reviewof the evidence comparing insulin (human or animal) with analogue insulins. 18th expert committee on the selection and use of Essential medicines. 1-51 (2011). www.who.int/selection medicines/committees/expert/18/applications/Insulin review.pdf
8. Vardi M, Jacobson E, Nini A, Bitterman H. Intermediate acting versus long acting insulin for Type I diabetes mellitus. Cochrane Database Syst. Rev. (3), CD0062979 (2008).
9. Horvath K, Jeitler K, Berghold A et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for Type II diabetes mellitus. Cochrane Database Syst. Rev. (2), CD005613 (2007).
10. Holden SE, Poole CD, Morgan CL, Currie CJ. Evaluation of the incremental cost to the National Health Service of prescribing analogue insulin. BMJ Open 1(2), e000258 (2011).
11. NICE. Guidance on the use of long-acting insulin analogues for the treatment of diabetes-insulin glargine (2002). www.nice.org.uk/guidance/ta53/documents/final-appraisal-determination-longacting-insulin-analogues-for-the-treatment-of-diabetes-insulin-glargine-2
12. Raskin P, Klaff L, Bergenstal R, Hallé JP, Donley D, Mecca T. A 16-week comparison of the novel insulin analog insulin glargine (HOE901) and NPH human insulin used with insulin lispro in patients with Type I diabetes. Diabetes Care 23(11), 1666-1671 (2000).
13. Herwig J, Scholl-Schilling G, Bohles H. Glycaemic control and hypoglycaemia in children, adolescents and young adults with unstable Type I diabetes mellitus treated with insulin glargine or intermediate-acting insulin. J. Pediatr. Endocrinol. Metab. 20(4), 517-525 (2007).
14. Schreiber SA, Russmann A. Long-term efficacy of insulin glargine therapy with an educational programme in Type I diabetes patients in clinical practice. Curr. Med. Res. Opin. 23(12), 3131-3136 (2006).
15. Salemyr J, Bang P, örtqvist E. Lower HbA1c after 1 year, in children with Type I diabetes treated with insulin glargine vs NPH insulin from diagnosis: a retrospective study. Pediatr. Diabetes 12(5), 501-505 (2011).
16. MINAS GERAIS. Secretaria de Estado de Saúde de Minas Gerais. Resolução SES-MG No 2359 de 17 de junho de 2010-Dispõe sobre o Protocolo Clínico e Diretrizes Terapêuticas para a utilização de análogo Glargina em portadores de diabetes mellitus Tipo I (DM1). Diário da Imprensa Oficial de Minas Gerais Poder Executivo, Belo Horizonte. 10(23), 1-27 (2010). http://ws.mpmg.mp.br/biblio/informa/180613576.htm
17. Centro Colaborador do SUS para Avaliação de Tecnologias, Excelencia em Saúde C. DIRETRIZES METODOLÓ GICAS Detalhamento acadêmico. 1-47 (2015). www.ccates.org.br/content/ pdf/PUB 1437678333.pdf
18. American Diabetes Association. Standards of medical care in diabetes-2015. Diabetes Care 38(Suppl. 1), S01-S98 (2015).
19. Lassere MN, Johnson KR, Boers M et al. Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. J. Rheumatol. 34(3), 607-615 (2007).
20. Canadian Agency for Drugs and Technologies in Health. Optimal therapy recommendations for the prescribing and use of insulin analogues. COMPUS 2(7), 87 (2009).
21. Singh SR, Ahmad F, Lal A, Yu C, Bai Z, Bennett H. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ 180(4), 385-397 (2009).
22. Mendes AB V, Fittipaldi JAS, Neves RCS, Chacra AR, Moreira ED. Prevalence and correlates of inadequate glycaemic control: results from a nationwide survey in 6671 adults with diabetes in Brazil. Acta Diabetol. 47(2), 137-145 (2010).
23. Garg SK, Paul JM, Karsten JI, Menditto L, Gottlieb PA. Reduced severe hypoglycemia with insulin glargine in intensively treated adults with Type I Diabetes. Diabetes Technol. Ther. 6(5), 589-595 (2004).
24. Cameron CG, Bennett HA. Cost-effectiveness of insulin analogues for diabetes mellitus. Can. Med. Assoc. J. 180(4), 400-407 (2009).
25. Sanchesa ACC, Correrb CJ, Venson R, Pontarolo R. Revisiting the efficacy of long-acting insulin analogues on adults with Type I diabetes using mixed-treatment comparisons. Diabetes Res. Clin. Pract. 94(3), 333-339 (2011).
26. Tricco AC, Ashoor HM, Antony J et al. Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with Type I diabetes: systematic review and network meta-analysis. BMJ 349, 1-13 (2014).
27. Laranjeira FO, Silva EN, Pereira MG. Budget impact of long-acting insulin analogues: the case in Brazil. PLoS ONE 11(12), e0167039 (2016).
28. NICE. Diabetes mellitus Type I and Type II: insulin glargine biosimilar (Abasaglar). NICE Guidance (2015) ESNM64. www.nice.org.uk/advice/esnm64/chapter/key-points-from-the-evidence
29. US FDA. FDA approves Basaglar, the first 'follow-on' insulin glargine product to treat diabetes (2015). www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm477734.htm
30. Yamamoto C, Miyoshi H, Fujiwara Y et al. Degludec is superior to glargine in terms of daily glycemic variability in people with Type I diabetes mellitus. Endocrine J. 63(1), 53-60 (2016).
31. Evans M, Chubb B, Gundgaard J. Cost-effectiveness of Insulin degludec versus insulin glargine in adults with Type I and Type II diabetes mellitus. Diabetes Ther. 8(2), 275-291 (2017).